Stem Cell Transplant for Common Variable Immunodeficiency

(CVID/PIRD Trial)

This trial explores a new treatment for Common Variable Immunodeficiency (CVID) and similar immune disorders using a hematopoietic stem cell transplant (HSCT). Researchers are testing whether this approach, which uses donor stem cells with a specific preparation process, can benefit individuals who haven't succeeded with other treatments. It targets those living with CVID or similar conditions who have not responded well to certain medications. Participants should have already tried and not benefited from treatments like mycophenolate mofetil and Rituximab. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that hematopoietic stem cell transplantation (HSCT) might benefit people with common variable immunodeficiency (CVID). Many patients experience improvements, particularly when infections are well-managed. For instance, one study found that 87% of patients who survived the treatment had no ongoing or returning infections.

However, HSCT carries risks. Some studies highlight a high likelihood of complications shortly after the transplant, such as graft versus host disease (GvHD), where the new cells attack the body. Another study reported a 68% survival rate, which increased to 84% when early complications were excluded.

Unlike standard treatments for Common Variable Immunodeficiency (CVID), which often include immunoglobulin replacement therapy to manage symptoms, hematopoietic stem cell transplant (HSCT) aims to address the root cause of the condition by essentially rebuilding the immune system. This treatment is unique because it involves transferring healthy stem cells from a donor, which can potentially lead to a long-term solution rather than just temporary symptom relief. Researchers are excited about HSCT because it has the potential to offer a more permanent and comprehensive treatment, potentially leading to a full immune system reset and significantly improving patients' quality of life.

Research has shown that hematopoietic stem cell transplant (HSCT) can benefit people with common variable immunodeficiency (CVID). In this trial, participants will receive an allogenic, fully or partially HLA-matched stem cell transplant. Studies have found that most patients with CVID who undergo this treatment experience positive outcomes. Specifically, about 85% of patients survive three years post-transplant. This suggests that HSCT could be a promising method to improve health for those with CVID. However, there is a high risk of serious complications shortly after the transplant.¹²³⁶⁷